BioAtla, Inc. (BCAB) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
N/A
—
5yr avg: 2.17
30Y Low1.7·High5.5
ROE
↓
N/A
—
5yr avg: -90.5%
30Y Low-164%·High-45%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BCAB Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
BioAtla, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5M | $33M | $29M | $118M | $321M | $678M | $1.1B | — | — |
| Enterprise Value | $4M | $32M | $-19493435 | $9M | $110M | $439M | $907M | — | — |
| P/E Ratio → | -0.09 | — | — | — | — | — | — | — | — |
| P/S Ratio | 2.56 | 16.70 | 2.61 | — | — | 2713.75 | 2668.76 | — | — |
| P/B Ratio | — | — | 2.01 | 1.66 | 1.78 | 3.22 | 5.45 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
BCAB EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 16.24 | -1.77 | — | — | 1755.32 | 2114.16 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
BCAB Profitability
Margins and return-on-capital ratios measuring operating efficiency
BioAtla, Inc. earns an operating margin of -2965.3%. Operating margins have compressed from -672.2% to -2965.3% over the past 3 years, signaling potential cost pressures or competitive headwinds.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 91.6% | — | — | 100.0% | -4546.4% | -398.4% | -147.5% |
| Operating Margin | -2965.3% | -2965.3% | -672.2% | — | — | -38576.0% | -7016.1% | -543.6% | -265.7% |
| Net Profit Margin | -2980.3% | -2980.3% | -634.3% | — | — | -38160.8% | -8357.3% | -573.0% | -272.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -164.3% | -98.4% | -53.8% | -45.3% | -46.6% | — | — |
| ROA | -179.9% | -179.9% | -81.1% | -71.5% | -43.9% | -38.2% | -28.2% | -229.4% | -174.2% |
| ROIC | — | — | — | — | — | — | — | — | — |
| ROCE | -398.2% | -398.2% | -114.5% | -88.2% | -49.5% | -43.1% | -30.8% | — | -379.4% |
BCAB Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $7M exceeds total debt of $6M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.06 | 0.03 | 0.02 | 0.03 | 0.00 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -3.38 | -1.54 | -1.17 | -1.14 | -1.13 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -31799.67 | -24.81 | -17.34 | -29.54 |
Net cash position: cash ($7M) exceeds total debt ($6M)
BCAB Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.37x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 4.11x to 0.37x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.37 | 0.37 | 3.52 | 4.11 | 9.53 | 12.48 | 7.46 | 0.17 | 1.38 |
| Quick Ratio | 0.37 | 0.37 | 3.52 | 4.11 | 9.53 | 12.48 | 7.46 | 0.17 | 1.38 |
| Cash Ratio | 0.32 | 0.32 | 3.37 | 3.93 | 9.32 | 12.36 | 7.40 | 0.14 | 1.18 |
| Asset Turnover | — | 0.14 | 0.21 | — | — | 0.00 | 0.00 | 0.56 | 0.64 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
BCAB Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
BioAtla, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $1M | $971467 | $955551 | $778545 | $691225 | $673272 | $673272 | $431772 |
Peer Comparison
Compare BCAB with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BCABYou | $5M | -0.1 | — | — | 100.0% | -2965.3% | — | — | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 AGEN | $132M | -1102.9 | — | — | 90.3% | -18.0% | — | — | — |
 MGNX | $186M | -2.5 | — | — | — | -48.7% | -86.9% | -1879.3% | — |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 MIRM | $5B | -219.0 | 2461.9 | 94.2 | 80.7% | -4.2% | -8.6% | -5.0% | 151.5 |
 ARVN | $652M | -8.0 | — | — | 98.0% | -43.8% | -16.2% | -22.4% | — |
 NKTR | $2B | -8.6 | — | — | — | -253.7% | -217.9% | -75.2% | — |
 AGIO | $2B | -3.9 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 REGN | $74B | 17.1 | 17.8 | 18.1 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
| Healthcare Median | — | 21.8 | 14.1 | 18.5 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See BCAB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BCAB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BCAB vs IMVT
Side-by-side business, growth, and profitability comparison vs Immunovant, Inc..
Start ComparisonBCAB — Frequently Asked Questions
Quick answers to the most common questions about buying BCAB stock.
What is BioAtla, Inc.'s P/E ratio?
BioAtla, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
Is BCAB stock overvalued?
Based on historical data, BioAtla, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are BioAtla, Inc.'s profit margins?
BioAtla, Inc. has 100.0% gross margin and -2965.3% operating margin.